期刊文献+

卵巢癌耐药性研究进展 被引量:2

Progress in mechanism of chemoresistance of ovarian cancer
下载PDF
导出
摘要 卵巢癌是女性致死率最高的恶性肿瘤之一。化疗是非常重要的治疗手段。但是肿瘤的耐药性严重影响了治疗效果。最近的证据表明细胞凋亡和抗凋亡的关键途径异常是肿瘤耐药发生和发展的关键因素之一。此外,新发现的这些途径之间的相互作用表明肿瘤耐药可能是多因素的。归根结底,肿瘤细胞在化疗药物作用下的存亡,决定于这一细胞的整体凋亡能力。在本文中,我们就促进细胞生存的生化途径和它们如何调节细胞的药敏性进行讨论,最后得到一些新的研究方向,从而阐明基本的耐药机制。 Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Recent evidence suggests that deregulation of key proand anti-apoptotic pathways is a key factor in the onset and maintenance of chemoresistance. Furthermore, the discovery of novel interactions between these pathways suggests that chemoresistance may be multi-factorial. Ultimately, the decision of the cancer cell to live or die in response to a chemotherapeutic agent is a consequence of the overall apoptotic capacity of that cell. In this review, we discuss the biochemical pathways believed to promote cell survival and how they modulate chemosensitivity. We then conclude with some new research directions by which the fundamental mechanisms of chemoresistance can be elucidated.
作者 赵营
出处 《国际医药卫生导报》 2007年第24期84-89,共6页 International Medicine and Health Guidance News
  • 相关文献

参考文献15

  • 1American Cancer Society Statistics for 2003. [www. cancer. org].
  • 2Eltabbakh GH and Awtrey CS: Current treatment for ovarian cancer[J]. Expert Opin Pharmacother 2001, 2:109- 124.
  • 3Gatti L, Supino R, Perego Caserini C, Carenini N, P, Pavesi R, Righetti SC, Zuco V and Zunino F: hpoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response[J]. Cell Death Differ 2002,9:1352-1359
  • 4Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C and Riccardi R: The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin Eur J Cancer 2001, 37:930-938
  • 5Schneiderman D, Kim J-M, Senterman M and Tsang BK: Sustained suppression of Fas ligand expression in cisplatinresistant human ovarian surface epithelial cancer cells[J]. Apoptosis 1999, 4:271-282.
  • 6Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG and Tsang BK: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins[J]. Endocrinology 2001, 142:370-380.
  • 7Verhagen AM, Coulson gJ and Vaux DL: Inhibitor of apoptosis proteins and their relatives: [J]. Genome Biol IAPs and other BIRPs 2001, 2:REVIEWS3009.
  • 8Sasaki H, Sheng Y, Kotsuji F and Tsang BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells[M]. Cancer Res 2000, 60:5659-5666.
  • 9Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV and Cheng JQ: AKT2 inhi- bition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASKI: Implication of AKT2 in chemoresistance[J]. J Biol them 2003.
  • 10Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK: p53 is a Determinant of Xiap/Akt-Mediated Chemoresistance in Human Ovarian Cancer Ceils [J]. Cancer Res 2003, In Press.

同被引文献4

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部